Disappointing Topline Results for Clazosentan in Aneurysmal SAH Disappointing Topline Results for Clazosentan in Aneurysmal SAH

Clazosentan failed to prevent clinical deterioration as a result of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage in the phase 3 REACT trial.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news